Letter to the Editor
Impressive response to four cemiplimab cycles of a sonidegib-resistant giant basosquamous carcinoma of the midface
No abstract is available for this article.
Conflicts of interest
T.G. has received speakers and/or advisory board honoraria from BMS, Sanofi-Genzyme, MSD, Novartis Pharma, Roche, Abbvie, Almirall, Janssen, Lilly, Pfizer, Pierre Fabre, Merck-Serono and outside the submitted work. L.S. has received speakers and/or advisory board honoraria from BMS, Sun-Pharma, Pierre Fabre, MSD and Novartis. I.S., M.N. and A.T. have no conflict of interest to declare.
Open Research
Data availability statement
Data are available from the corresponding author on reasonable request.
